129 related articles for article (PubMed ID: 37604085)
1. Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine.
Yeung J; Wang T; Shi PY
Curr Opin Virol; 2023 Oct; 62():101347. PubMed ID: 37604085
[TBL] [Abstract][Full Text] [Related]
2. Intranasal COVID-19 vaccines: From bench to bed.
Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
[TBL] [Abstract][Full Text] [Related]
3. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
4. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals.
Ye ZW; Ong CP; Tang K; Fan Y; Luo C; Zhou R; Luo P; Cheng Y; Gray VS; Wang P; Chu H; Chan JF; To KK; Chen H; Chen Z; Yuen KY; Ling GS; Yuan S; Jin DY
Cell Mol Immunol; 2022 May; 19(5):588-601. PubMed ID: 35352010
[TBL] [Abstract][Full Text] [Related]
6. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
[TBL] [Abstract][Full Text] [Related]
7. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
8. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
Chavda VP; Vora LK; Pandya AK; Patravale VB
Drug Discov Today; 2021 Nov; 26(11):2619-2636. PubMed ID: 34332100
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
Dhama K; Dhawan M; Tiwari R; Emran TB; Mitra S; Rabaan AA; Alhumaid S; Alawi ZA; Al Mutair A
Hum Vaccin Immunother; 2022 Nov; 18(5):2045853. PubMed ID: 35258416
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
12. A non-transmissible live attenuated SARS-CoV-2 vaccine.
Adler JM; Martin Vidal R; Voß A; Kunder S; Nascimento M; Abdelgawad A; Langner C; Vladimirova D; Osterrieder N; Gruber AD; Kunec D; Trimpert J
Mol Ther; 2023 Aug; 31(8):2391-2407. PubMed ID: 37263272
[TBL] [Abstract][Full Text] [Related]
13. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
[TBL] [Abstract][Full Text] [Related]
14. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
Pilapitiya D; Wheatley AK; Tan HX
EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404
[TBL] [Abstract][Full Text] [Related]
15. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
16. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
17. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
18. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
[TBL] [Abstract][Full Text] [Related]
19. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
20. Oral and intranasal vaccines against SARS-CoV-2: Current progress, prospects, advantages, and challenges.
Kar S; Devnath P; Emran TB; Tallei TE; Mitra S; Dhama K
Immun Inflamm Dis; 2022 Apr; 10(4):e604. PubMed ID: 35349752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
